MedTrace Logo

Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes

NCT02213484 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2017-03-15

No results posted yet for this study

Summary

The primary objective of this study is to determine whether specific patterns of circulating micro-ribonucleic acids (miRNAs) are associated with aortic aneurysm and dissection in patients with hereditary aortopathy syndromes. The most common of these syndromes is Marfan Syndrome (MFS), but several other recognized aortopathy syndromes are well characterized. The investigators propose the use of a simple blood test, from which miRNA profiles can be measured in individuals with aortopathy syndromes to be compared with miRNAs observed in a control population that has no known predisposition for aortic disease. The investigators hypothesize that microRNA profiles in individuals with Marfan syndrome, and related disorders, will be distinct from those seen in a control group. The investigators predict that up- or down-regulation of certain miRNAs will correlate with the presence and severity of aortic aneurysm, responses to medical therapy, and ultimately could be used to determine when an individual may be at risk of dissection.

Conditions

  • Marfan Syndrome
  • Loeys-Dietz Syndrome
  • Thoracic Aortic Aneurysm and Dissection Syndromes
  • Ehlers-Danlos Type IV Syndrome
  • Turner Syndrome

Sponsors & Collaborators

  • University of Colorado, Denver

    lead OTHER

Principal Investigators

  • Kathryn C Chatfield, MD, PhD · University of Colorado Denver, Children's Hospital Colorado

Eligibility

Min Age
30 Days
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-07-01
Primary Completion
2016-07-01
Completion
2016-07-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02213484 on ClinicalTrials.gov